New Treatment Paradigms in Second-line Therapy for Pancreatic Cancer

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: June 01, 2016
Expiration Date: June 01, 2017

Expected time to complete this activity as designed: 15 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

This activity will describe treatment options in the second-line setting for patients with advanced (metastatic) pancreatic cancer. Dr. Tanios Bekaii-Saab, Co-Leader of the Gastrointestinal Cancer Program at the Mayo Clinic Cancer Center, and Senior Associate Consultant, Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, explains new treatment paradigms in second-line therapy given the approval of nanoliposomal irinotecan, including therapeutic selection based on prior therapy and toxicities of currently available agents.

Target Audience

This activity is designed for community oncologists, pharmacists, and allied health care professionals who may provide care to patients with pancreatic cancer.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize clinical trial data supporting newly approved agents for patients with metastatic pancreatic cancer who are experiencing disease progression following gemcitabine-based therapy, including safety, efficacy, treatment-related adverse events and appropriate patient types, as well as limitations of the trial data

  • Outline therapeutic strategies for second-line therapy in patients with metastatic pancreatic cancer, focusing on practical approaches to optimizing therapy for individual patients, including proactive strategies for minimizing the impact of treatment-related adverse events


New Treatment Paradigms in Second-line Therapy for Pancreatic Cancer – Tanios Bekaii-Saab, MD, FACP

Instructions for Participation and Credit

This activity is eligible for credit through June 1, 2017. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Tanios Bekaii-Saab, MD, FACP
Co-Leader, Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Senior Associate Consultant
Division of Hematology and Oncology
Mayo Clinic
Phoenix, Arizona

Dr. Tanios Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon, followed by a residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana. He completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts. Dr. Bekaii-Saab joined the faculty at the Mayo Clinic in May 2016 as Co-Leader of the Gastrointestinal Cancer Program at the Mayo Clinic Cancer Center, and Senior Associate Consultant, Division of Hematology and Oncology. He was previously at Ohio State University - Arthur G. James Cancer Hospital and Solove Research Institute as a tenured Professor of Medicine and Pharmacy, and Section Chief for the Gastrointestinal Cancer Program.

Dr. Bekaii-Saab is actively involved in the American Society of Clinical Oncology, American Association for Cancer Research, American Society for Clinical Pharmacology and Therapeutics, and the Alliance cooperative group. He also serves as a member on the Colorectal Cancer Panel for the National Comprehensive Cancer Network (NCCN). In addition, he has served as a reviewer for more than 50 journals, as journal editorial board member of Journal of the National Comprehensive Cancer Network, World Journal of Hepatology, US Oncological Review, and OncLive, and has authored more than 350 publications and abstracts in journals including Journal of Clinical Oncology, Annals of Oncology, and Clinical Cancer Research.

Dr. Bekaii-Saab’s research interests include experimental therapeutics/translational research focused on gastrointestinal malignancies, molecular targeted and immune therapies, including various collaborations with a number of scientists from different laboratories. He is the principal investigator on numerous clinical trials supported through research grants from the National Cancer Institute (NCI) and the NCCN. He is also the recipient of numerous research grants from various industry partners. Dr. Bekaii-Saab is also the recipient of the prestigious NCI clinical investigator team leadership award and the ASCO leadership program development award. Additionally, he has been listed in U.S. News and World Report’s Top Doctors and is one of the Best Doctors in America.


MediCom WOrldwide, Inc. CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 0827-0000-16-095-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Tanios Bekaii-Saab has received honoraria as a consultant from Celgene Corporation, Genentech, Inc., Merrimack Pharmaceuticals, Inc., and Taiho Pharmaceutical Co., Ltd.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, and Alan J. Vogenberg, RPh, FASCP, Clinical Consultant, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Bekaii-Saab has indicated that he does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Bekaii-Saab has indicated that he does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Merrimack Pharmaceuticals, Inc.

©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

MediCom Worldwide, Inc. would like to thank Celgene Corporation for their educational support of

©2020 MediCom Worldwide, Inc. All rights reserved